** Shares of genomic medicine company Sangamo Therapeutics SGMO.O rise 12.24% to $2.20 premarket
** Co says U.S. Food and Drug Administration has cleared co's application to start human trial for ST-503
** SGMO plans to initiate enrollment of patients in the early-to-mid stage study for ST-503 in mid-2025
** The therapy ST-503 is being studied for the treatment of intractable pain due to idiopathic small fiber neuropathy (iSFN), a type of chronic nerve pain
** Up to last close, stock had more than tripled YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。